PROTEIN POLYMER TECHNOLOGIES ANNOUNCES THE APPOINTMENT OF STEPHEN REITZLER AS VICE PRESIDENT OF CLINICAL AND REGULATORY AFFAIRS

 

SAN DIEGO, October 3 -- Protein Polymer Technologies, Inc. (OTC Bulletin Board: PPTI) a biotechnology device company that is a pioneer in protein design and synthesis, announced today the addition of Stephen Reitzler as Vice President, Clinical and Regulatory Affairs, effective October 3, 2005. Reitzler's responsibilities will include strategic and executional oversight for all U.S. clinical and regulatory matters, including filings and interaction with regulatory authorities.
Reitzler joins PPTI with more than twenty-five years of experience in the strategic management of regulatory, compliance and clinical research. Prior to joining the company, Mr. Reitzler served as V.P. Regulatory Affairs and Quality Assurance for INNERCOOL therapies and previously was V.P. Regulatory Affairs and Quality Assurance for NuVasive Incorporated. He has broad experience in both 510 (k) and PMA applications, and ISO/FDA GMP audits.
"Stephen brings exceptional clinical and regulatory expertise to PPTI and we welcome him to our executive team," said William N. Plamondon III, PPTI's Chief Executive Officer. "His impressive background will prove to be extremely valuable and further strengthen our leadership in clinical and regulatory affairs as we advance toward the important product development milestones that we have set for the company."
Mr. Reitzler played an important role at United States Surgical Corporation, a highly successful medical device company that took a creative and cutting edge approach to the Food and Drug Administration process. He also helped start a highly successful and large consulting practice in San Diego, Advanced Bioresearch Associates, where he was head of regulatory affairs and worked on a variety of projects such as an implantable heart, an artificial liver and a chemotherapy drug.
"I am excited to join PPTI at this point in its transformation and am confident that my experience can add value as we go forward and execute our development and commercialization strategies," commented Mr. Reitzler. "I am impressed by the current product pipeline and the value that it will provide."

 

Contacts

J. Thomas Parmeter, Ph.D. Chairman Protein Polymer Technologies, Inc. (858) 558-6064 info@ppti.com

Erin Davis Director of Communications and Investor Relations Protein Polymer Technologies, Inc. (858) 558-6064 x 120 edavis@ppti.com

About Protein Polmer Technologies

Protein Polymer Technologies, Inc., is a biotechnology company that discovers and develops innovative therapeutic devices to improve medical and surgical outcomes. The Company focuses on developing technology and products to be used for soft tissue augmentation, tissue adhesives and sealants, wound healing support and drug delivery devices. Protein Polymer Technologies' proprietary protein-based biomaterials are uniquely tailored to optimize clinical performance and contain no human or animal components that could potentially transmit or cause disease. The company is headquartered in San Diego, California. For additional information about the company, please visit http://www.ppti.comhttp://www.ppti.com.
To date, PPTI has been issued twenty-six U.S. Patents on its core technology with corresponding issued and pending patents in key international markets.

Safe Harbo

This press release contains forward-looking statements that are based on management’s views and expectations. Actual results could differ materially from those expressed here; further, the Company is not obligated to comment specifically on those differences. Risks associated with the Company’s activities include raising adequate capital to continue operations scientific and product development uncertainties, competitive products and approaches, continuing collaborative partnership interest and funding, regulatory testing and approvals, and manufacturing scale up. The reader is encouraged to refer to the Company’s 2004 Annual Report Form 10-KSB, and 10KSB/A and other recent filings with the Securities and Exchange Commission, copies of which are available from the Company, to further ascertain the risks associated with the above statements.